124 related articles for article (PubMed ID: 37969095)
21. Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.
Taniguchi S; Yamauchi T; Choi I; Fukuhara N; Potluri J; Salem AH; Hong WJ; Honda H; Nishimura Y; Okubo S; Usuki K
Jpn J Clin Oncol; 2021 May; 51(6):857-864. PubMed ID: 33712849
[TBL] [Abstract][Full Text] [Related]
22. Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia.
Ivanov V; Yeh SP; Mayer J; Saini L; Unal A; Boyiadzis M; Hoffman DM; Kang K; Addo SN; Mendes WL; Fathi AT
Future Oncol; 2022 Aug; 18(26):2879-2889. PubMed ID: 35852098
[TBL] [Abstract][Full Text] [Related]
23. Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report.
Wang L; Lin N
Medicine (Baltimore); 2021 Feb; 100(6):e24703. PubMed ID: 33578607
[TBL] [Abstract][Full Text] [Related]
24. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
Freise KJ; Shebley M; Salem AH
J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
[TBL] [Abstract][Full Text] [Related]
25. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.
Konopleva M; Thirman MJ; Pratz KW; Garcia JS; Recher C; Pullarkat V; Kantarjian HM; DiNardo CD; Dail M; Duan Y; Chyla B; Potluri J; Miller CL; Wei AH
Clin Cancer Res; 2022 Jul; 28(13):2744-2752. PubMed ID: 35063965
[TBL] [Abstract][Full Text] [Related]
26. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
[TBL] [Abstract][Full Text] [Related]
27. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Davids MS; Lampson BL; Tyekucheva S; Wang Z; Lowney JC; Pazienza S; Montegaard J; Patterson V; Weinstock M; Crombie JL; Ng SY; Kim AI; Jacobson CA; LaCasce AS; Armand P; Arnason JE; Fisher DC; Brown JR
Lancet Oncol; 2021 Oct; 22(10):1391-1402. PubMed ID: 34534514
[TBL] [Abstract][Full Text] [Related]
28. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Kadia TM; Reville PK; Wang X; Rausch CR; Borthakur G; Pemmaraju N; Daver NG; DiNardo CD; Sasaki K; Issa GC; Ohanian M; Montalban-Bravo G; Short NJ; Jain N; Ferrajoli A; Bhalla KN; Jabbour E; Takahashi K; Malla R; Quagliato K; Kanagal-Shamanna R; Popat UR; Andreeff M; Garcia-Manero G; Konopleva MY; Ravandi F; Kantarjian HM
J Clin Oncol; 2022 Nov; 40(33):3848-3857. PubMed ID: 35704787
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL
J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
Rutherford SC; Abramson JS; Bartlett NL; Barta SK; Khan N; Joyce R; Maddocks K; Ali-Shaw T; Senese S; Yuan Y; Westin J; Leonard JP
Lancet Haematol; 2021 Nov; 8(11):e818-e827. PubMed ID: 34634256
[TBL] [Abstract][Full Text] [Related]
31. Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors.
Agarwal SK; Tong B; Bueno OF; Menon RM; Salem AH
Adv Ther; 2018 Nov; 35(11):2015-2023. PubMed ID: 30264382
[TBL] [Abstract][Full Text] [Related]
32. Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach.
Bhatnagar S; Mukherjee D; Salem AH; Miles D; Menon RM; Gibbs JP
Cancer Chemother Pharmacol; 2021 Apr; 87(4):465-474. PubMed ID: 33398386
[TBL] [Abstract][Full Text] [Related]
33. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger J; Borthakur G; Takahashi K; Estrov Z; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Sasaki K; Kanagal-Shamanna R; Patel K; Jorgensen J; Garg N; Wang X; Sondermann K; Cruz N; Wei C; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda W
N Engl J Med; 2019 May; 380(22):2095-2103. PubMed ID: 31141631
[TBL] [Abstract][Full Text] [Related]
34. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
[TBL] [Abstract][Full Text] [Related]
36. [Venetoclax and azacitidine induced cytogenetic response in an elderly patient with IDH2- and DNMT3A-mutated refractory acute myeloid leukemia].
Kunisada K; Matsuoka A; Yoshida S; Taoka T
Rinsho Ketsueki; 2022; 63(12):1621-1625. PubMed ID: 36653133
[TBL] [Abstract][Full Text] [Related]
37. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
Pollyea DA; Pratz K; Letai A; Jonas BA; Wei AH; Pullarkat V; Konopleva M; Thirman MJ; Arellano M; Becker PS; Chyla B; Hong WJ; Jiang Q; Potluri J; DiNardo CD
Am J Hematol; 2021 Feb; 96(2):208-217. PubMed ID: 33119898
[TBL] [Abstract][Full Text] [Related]
39. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.
Pollyea DA; Pratz KW; Wei AH; Pullarkat V; Jonas BA; Recher C; Babu S; Schuh AC; Dail M; Sun Y; Potluri J; Chyla B; DiNardo CD
Clin Cancer Res; 2022 Dec; 28(24):5272-5279. PubMed ID: 36007102
[TBL] [Abstract][Full Text] [Related]
40. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
